Bioverativ (NASDAQ:BIVV) was downgraded by stock analysts at Piper Jaffray Companies from an “overweight” rating to a “neutral” rating in a note issued to investors on Monday, The Fly reports.
BIVV has been the subject of a number of other reports. Zacks Investment Research upgraded shares of Bioverativ from a “hold” rating to a “buy” rating and set a $62.00 price target for the company in a report on Monday, January 8th. Morgan Stanley reiterated an “underweight” rating and set a $47.00 price target (up from $45.00) on shares of Bioverativ in a report on Friday, October 6th. Royal Bank of Canada lifted their price target on shares of Bioverativ to $68.00 and gave the stock a “market perform” rating in a report on Thursday. Deutsche Bank set a $53.00 price target on shares of Bioverativ and gave the stock a “hold” rating in a report on Monday, November 20th. Finally, Jefferies Group lifted their price target on shares of Bioverativ to $79.00 and gave the stock a “buy” rating in a report on Thursday. One research analyst has rated the stock with a sell rating, nine have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $62.53.
Shares of Bioverativ (NASDAQ BIVV) traded up $1.36 during midday trading on Monday, hitting $64.11. 829,100 shares of the stock were exchanged, compared to its average volume of 999,962. The stock has a market capitalization of $11,230.00 and a P/E ratio of 15.67. Bioverativ has a 1-year low of $40.99 and a 1-year high of $65.09.
Bioverativ (NASDAQ:BIVV) last issued its quarterly earnings results on Thursday, October 26th. The biotechnology company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.25. The business had revenue of $291.60 million during the quarter, compared to the consensus estimate of $285.45 million. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. The firm’s revenue for the quarter was up 27.2% on a year-over-year basis. sell-side analysts forecast that Bioverativ will post 2.69 earnings per share for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in the stock. Hendershot Investments Inc. grew its holdings in Bioverativ by 4.8% in the fourth quarter. Hendershot Investments Inc. now owns 17,662 shares of the biotechnology company’s stock valued at $952,000 after purchasing an additional 807 shares during the period. State of Alaska Department of Revenue purchased a new stake in Bioverativ in the fourth quarter valued at approximately $428,000. Acadian Asset Management LLC grew its holdings in Bioverativ by 54.7% in the fourth quarter. Acadian Asset Management LLC now owns 1,246,815 shares of the biotechnology company’s stock valued at $67,229,000 after purchasing an additional 441,084 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in Bioverativ by 8.8% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 343,731 shares of the biotechnology company’s stock valued at $18,534,000 after purchasing an additional 27,800 shares during the period. Finally, Gateway Investment Advisers LLC lifted its position in Bioverativ by 40.1% during the fourth quarter. Gateway Investment Advisers LLC now owns 131,579 shares of the biotechnology company’s stock valued at $7,095,000 after buying an additional 37,667 shares in the last quarter. Hedge funds and other institutional investors own 96.04% of the company’s stock.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.